FibroGen Inc (NASDAQ:FGEN) SVP Pat Cotroneo sold 1,011 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $57.35, for a total value of $57,980.85. Following the completion of the sale, the senior vice president now directly owns 220,422 shares in the company, valued at $12,641,201.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Pat Cotroneo also recently made the following trade(s):
- On Thursday, June 14th, Pat Cotroneo sold 10,069 shares of FibroGen stock. The stock was sold at an average price of $59.47, for a total value of $598,803.43.
Shares of FGEN traded up $0.60 during mid-day trading on Wednesday, reaching $59.60. The company had a trading volume of 294,400 shares, compared to its average volume of 507,055. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.19. FibroGen Inc has a 52 week low of $40.74 and a 52 week high of $68.55. The stock has a market cap of $4.80 billion, a P/E ratio of -34.05 and a beta of 1.82.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.31. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%. The firm had revenue of $43.95 million for the quarter, compared to analysts’ expectations of $28.70 million. equities analysts anticipate that FibroGen Inc will post -1.32 EPS for the current year.
A number of analysts have recently commented on FGEN shares. Mizuho raised FibroGen from a “neutral” rating to a “buy” rating and set a $61.00 price target on the stock in a research report on Tuesday, May 15th. BidaskClub raised FibroGen from a “hold” rating to a “buy” rating in a research report on Thursday, May 24th. ValuEngine raised FibroGen from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, June 8th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. FibroGen has a consensus rating of “Buy” and a consensus target price of $76.40.
A number of hedge funds have recently added to or reduced their stakes in FGEN. Mackay Shields LLC bought a new position in FibroGen in the 1st quarter valued at approximately $1,081,000. American Century Companies Inc. lifted its position in FibroGen by 1.5% in the 1st quarter. American Century Companies Inc. now owns 84,949 shares of the biopharmaceutical company’s stock valued at $3,925,000 after acquiring an additional 1,294 shares in the last quarter. Prudential Financial Inc. lifted its position in FibroGen by 28.2% in the 1st quarter. Prudential Financial Inc. now owns 374,159 shares of the biopharmaceutical company’s stock valued at $17,286,000 after acquiring an additional 82,340 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in FibroGen by 6.7% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 33,434 shares of the biopharmaceutical company’s stock valued at $1,545,000 after acquiring an additional 2,093 shares in the last quarter. Finally, Swiss National Bank lifted its position in FibroGen by 6.0% in the 1st quarter. Swiss National Bank now owns 121,300 shares of the biopharmaceutical company’s stock valued at $5,604,000 after acquiring an additional 6,900 shares in the last quarter. 66.10% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Read More: Marijuana Stocks Future Looks Bright
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.